

RECEIVED
CENTRAL FAX CENTER
SEP 12 2006

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the above-referenced application. Kindly cancel Claim 52 and amend Claim 53-55, 57-60, and 62-63 as follows:


STATUS OF THE CLAIMS

1-51. (cancelled)

52. (CANCELLED)


53. (Currently amended) ~~The method of claim 52, wherein the hydroxydiphenyl ether has~~ A method of treating a subject in need of treatment for malaria, wherein the subject is infected with a malaria parasite, the method comprising the step of:

administering an antimalarial composition comprising a compound that is an inhibitor of fatty acid synthesis in the malaria parasite to the subject, wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl ether of the general formula 2 given below wherein the two phenyl rings (I & II) are joined by an oxygen atom (X=O) and either R₁ or R₂ represents a hydroxy (OH) group with the other being a hydrogen atom, respectively, or both being hydroxy groups, and wherein R₃ to R₁₀ of the phenyl rings I and II are selected from the group consisting of: chlorine, bromine, iodine, hydrogen, hydroxyl groups, aldehyde groups, keto groups, and ester groups.



Formula 2

54. (Currently amended) The method of claim ~~52~~ 53, wherein the inhibitor of fatty acid synthesis is triclosan having formula 1 given below:



Formula 1

55. (Currently amended) The method of claim 52-53, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.

56. (previously presented) The method of claim 55, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.

57. (Currently amended) The method of claim 52-53, wherein the composition is administered by injection.

58. (Currently amended) The method of claim 52-53, wherein the amount of the inhibitor of fatty acid synthesis administered is in the dosage range of 0.03 mg/kg to 100 mg/kg.

59. (Currently amended) The method of claim 52-53, wherein the compound inhibits FabI (enoyl ACP reductase) in the malaria parasite.

60. (Currently amended) The method of claim 52-53, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.

61. (previously presented) The method of claim 60, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.

62. (Currently amended) The method of claim 52-53, wherein the inhibitor of fatty acid synthesis in the malaria parasite is an inhibitor of FabI (enoyl-ACP reductase).

63. (Currently amended) The method of claim 52-53, wherein the malaria parasite is *P. falciparum*.